(CHE) Chemed - Ratings and Ratios
Hospice, Palliative, Plumbing, Drain Cleaning, Water Restoration
CHE EPS (Earnings per Share)
CHE Revenue
Description: CHE Chemed
Chemed Corporation is a healthcare services company operating primarily in the United States, providing hospice and palliative care through its VITAS segment, as well as plumbing and drain cleaning services through its Roto-Rooter segment. The companys diverse service offerings cater to both residential and commercial customers, generating revenue through a mix of company-owned branches, independent contractors, and franchisees.
From a financial perspective, Chemed Corp has demonstrated strong profitability, with a Return on Equity (ROE) of 26.03%, indicating effective use of shareholder capital. The companys Price-to-Earnings (P/E) ratio of 22.71 suggests a reasonable valuation relative to its earnings, while the forward P/E of 19.31 implies expected earnings growth. With a market capitalization of $6.82 billion, Chemed Corp is a mid-cap stock with a stable presence in the healthcare services sector.
Key Performance Indicators (KPIs) such as revenue growth, hospice admissions, and average daily census for VITAS, as well as revenue per user and customer count for Roto-Rooter, are crucial in evaluating Chemed Corps operational performance. Additionally, metrics like operating margins, cash flow generation, and debt-to-equity ratio provide insight into the companys financial health and ability to invest in growth initiatives. A thorough analysis of these KPIs is essential to understanding Chemed Corps investment potential.
To further assess Chemed Corps prospects, it is essential to examine industry trends, competitive positioning, and the companys strategic initiatives. The hospice care market is driven by an aging population and increasing demand for end-of-life care, while the plumbing services market is influenced by housing starts, renovation activity, and consumer spending. Chemed Corps ability to navigate these trends and maintain its market share will be critical to its long-term success.
CHE Stock Overview
| Market Cap in USD | 6,699m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1973-05-03 |
CHE Stock Ratings
| Growth Rating | -15.9% |
| Fundamental | 85.4% |
| Dividend Rating | 53.7% |
| Return 12m vs S&P 500 | -34.5% |
| Analyst Rating | 4.67 of 5 |
CHE Dividends
| Dividend Yield 12m | 0.42% |
| Yield on Cost 5y | 0.43% |
| Annual Growth 5y | 6.40% |
| Payout Consistency | 97.0% |
| Payout Ratio | 9.4% |
CHE Growth Ratios
| Growth Correlation 3m | -58% |
| Growth Correlation 12m | -51.6% |
| Growth Correlation 5y | 60.9% |
| CAGR 5y | -2.10% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.25 |
| Sharpe Ratio 12m | 0.84 |
| Alpha | -36.92 |
| Beta | 0.640 |
| Volatility | 22.30% |
| Current Volume | 159.2k |
| Average Volume 20d | 166.9k |
| Stop Loss | 433 (-3%) |
| Signal | -1.10 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (290.3m TTM) > 0 and > 6% of Revenue (6% = 150.7m TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 7.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.06% (prev 8.69%; Δ 0.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 426.8m > Net Income 290.3m (YES >=105%, WARN >=100%) |
| Net Debt (-104.3m) to EBITDA (419.3m) ratio: -0.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.6m) change vs 12m ago -4.23% (target <= -2.0% for YES) |
| Gross Margin 33.15% (prev 33.95%; Δ -0.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 145.5% (prev 134.6%; Δ 10.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 191.3 (EBITDA TTM 419.3m / Interest Expense TTM 2.03m) >= 6 (WARN >= 3) |
Altman Z'' 13.55
| (A) 0.13 = (Total Current Assets 491.4m - Total Current Liabilities 263.9m) / Total Assets 1.72b |
| (B) 1.65 = Retained Earnings (Balance) 2.83b / Total Assets 1.72b |
| warn (B) unusual magnitude: 1.65 — check mapping/units |
| (C) 0.22 = EBIT TTM 387.8m / Avg Total Assets 1.73b |
| (D) 5.52 = Book Value of Equity 2.87b / Total Liabilities 519.4m |
| Total Rating: 13.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.38
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 5.72% = 2.86 |
| 3. FCF Margin 14.79% = 3.70 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda 0.10 = 2.49 |
| 6. ROIC - WACC 16.44% = 12.50 |
| 7. RoE 24.53% = 2.04 |
| 8. Rev. Trend 95.64% = 4.78 |
| 9. Rev. CAGR 6.05% = 0.76 |
| 10. EPS Trend 39.11% = 0.98 |
| 11. EPS CAGR -1.83% = -0.23 |
What is the price of CHE shares?
Over the past week, the price has changed by -3.75%, over one month by +0.57%, over three months by -19.07% and over the past year by -22.59%.
Is Chemed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CHE is around 355.46 USD . This means that CHE is currently overvalued and has a potential downside of -20.37%.
Is CHE a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 582.3 | 30.4% |
| Analysts Target Price | 582.3 | 30.4% |
| ValueRay Target Price | 395.7 | -11.4% |
Last update: 2025-09-05 04:37
CHE Fundamental Data Overview
CCE Cash And Equivalents = 249.9m USD (last quarter)
P/E Trailing = 23.6471
P/E Forward = 18.2815
P/S = 2.6667
P/B = 5.5884
P/EG = 1.8294
Beta = 0.455
Revenue TTM = 2.51b USD
EBIT TTM = 387.8m USD
EBITDA TTM = 419.3m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 43.7m USD (from shortTermDebt, last quarter)
Debt = 43.7m USD (Calculated: Short Term 43.7m + Long Term 0.0)
Net Debt = -104.3m USD (from netDebt column, last quarter)
Enterprise Value = 6.49b USD (6.70b + Debt 43.7m - CCE 249.9m)
Interest Coverage Ratio = 191.3 (Ebit TTM 387.8m / Interest Expense TTM 2.03m)
FCF Yield = 5.72% (FCF TTM 371.4m / Enterprise Value 6.49b)
FCF Margin = 14.79% (FCF TTM 371.4m / Revenue TTM 2.51b)
Net Margin = 11.56% (Net Income TTM 290.3m / Revenue TTM 2.51b)
Gross Margin = 33.15% ((Revenue TTM 2.51b - Cost of Revenue TTM 1.68b) / Revenue TTM)
Tobins Q-Ratio = 2.26 (Enterprise Value 6.49b / Book Value Of Equity 2.87b)
Interest Expense / Debt = 1.77% (Interest Expense 772.0k / Debt 43.7m)
Taxrate = 24.40% (97.5m / 399.5m)
NOPAT = 293.2m (EBIT 387.8m * (1 - 24.40%))
Current Ratio = 1.86 (Total Current Assets 491.4m / Total Current Liabilities 263.9m)
Debt / Equity = 0.04 (Debt 43.7m / last Quarter total Stockholder Equity 1.20b)
Debt / EBITDA = 0.10 (Net Debt -104.3m / EBITDA 419.3m)
Debt / FCF = 0.12 (Debt 43.7m / FCF TTM 371.4m)
Total Stockholder Equity = 1.18b (last 4 quarters mean)
RoA = 16.90% (Net Income 290.3m, Total Assets 1.72b )
RoE = 24.53% (Net Income TTM 290.3m / Total Stockholder Equity 1.18b)
RoCE = 32.76% (Ebit 387.8m / (Equity 1.18b + L.T.Debt 0.0))
RoIC = 24.76% (NOPAT 293.2m / Invested Capital 1.18b)
WACC = 8.32% (E(6.70b)/V(6.74b) * Re(8.37%)) + (D(43.7m)/V(6.74b) * Rd(1.77%) * (1-Tc(0.24)))
Shares Correlation 3-Years: -18.18 | Cagr: -0.27%
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.94% ; FCFE base≈324.0m ; Y1≈342.4m ; Y5≈405.8m
Fair Price DCF = 458.5 (DCF Value 6.68b / Shares Outstanding 14.6m; 5y FCF grow 6.23% → 3.0% )
Revenue Correlation: 95.64 | Revenue CAGR: 6.05%
Rev Growth-of-Growth: 0.03
EPS Correlation: 39.11 | EPS CAGR: -1.83%
EPS Growth-of-Growth: -25.82
Additional Sources for CHE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle